# A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)

Source: https://onco.cc/trials/nct07672223/  
OnCo record `nct07672223` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of SYS6010, tislelizumab, toripalimab, durvalumab and other drugs in lung cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting.

## Summary

A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) is a phase 3, randomised interventional study registered as NCT07672223 by CSPC Megalith Biopharmaceutical Co.,Ltd., with a registry enrolment figure of 570 participants, started 2026-06-25 and due to reach its primary completion in 2029-09-30. Interventions recorded: SYS6010; Enlonstobart; Tislelizumab; Toripalimab ±+platinum-based doublet chemotherapy; Durvalumab; Pembrolizumab; Nivolumab. Conditions listed: Non-small Cell Lung Cancer. Primary outcome: Disease-Free Survival (DFS) assessed by the independent review committee (IRC). Lung eligibility wording from the registry: "Histologically confirmed squamous or non-squamous NSCLC". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07672223
- Phase: 3
- Setting: A Phase III, Randomized, Open-Label Study of SYS6010 in Combination With Anti-PD-(L)-1 Monoclonal Antibody Versus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy for Patients With Completely Resected Stage II-IIIB NSCLC Who Have No Actionable Genomic Alterations and Not Achieved a Major Pathological Response.
- Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
- Enrolled: 570

## Sources

- ClinicalTrials.gov NCT07672223: https://clinicaltrials.gov/study/NCT07672223

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [SYS6010](https://onco.cc/drugs/sys6010/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07672223.json